Societe Generale’s Regeneron Pharmaceuticals REGN Stock Holding History

Societe Generale’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	$5.89M	Buy	+16,880	New	+$6.5M	0.04%	352

Other funds holding REGN

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Societe Generale's REGN Position: Q2 2016 in Review

Societe Generale opened a new position in Regeneron Pharmaceuticals (REGN) in Q2 2016: 16,880 shares worth $5.89M. The stake represents 0.04% of the portfolio and ranks #352 among its holdings.

541 funds tracked by Wall St. Rank hold REGN as of Q2 2016.

Societe Generale held 16,880 shares of Regeneron Pharmaceuticals worth $5.89M as of Q2 2016.
Regeneron Pharmaceuticals was a new Societe Generale position in Q2 2016.
Regeneron Pharmaceuticals made up 0.04% of Societe Generale's portfolio in Q2 2016, its #352 holding.
541 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2016.

Based on Societe Generale's 13F filing for Q2 2016, filed 2 Aug 2016.